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ABSTRACT
Background: Splenic tumors are rare. Malignant fibrous
histiocytoma (MFH) of the spleen is one of the least
common primary splenic tumors. Review of the literature
shows that a laparoscopic resection has never been tried.
Method: We discuss the case of a 76-year-old man with a
7-cm MFH in the spleen and present a review of splenic
sarcomas.
Results: The patient underwent a successful laparoscopic
splenectomy; pathology revealed a rare undifferentiated
pleomorphic sarcoma of the spleen. A review of the in-
ternational literature identified 15 additional cases of pri-
mary splenic MFH. Survival was rarely longer than 15
months.
Conclusion: Malignant fibrous histiocytoma of the spleen
is an exceedingly rare tumor with a poor prognosis. In
experienced hands, laparoscopic splenectomy is a feasi-
ble operative choice for primary splenic sarcoma.
Key Words: Undifferentiated pleomorphic sarcoma, Ma-
lignant fibrous histiocytoma, Laparoscopic splenectomy.
INTRODUCTION
Laparoscopic splenectomy (LS) is one of the many suc-
cessful applications of minimally invasive surgical tech-
niques. Since the first laparoscopic splenectomy per-
formed in 1991 by Delaître, this approach has been
adopted as the procedure of choice to treat benign splenic
pathologies.1 However, data on laparoscopic splenic re-
section for malignant tumors is scarce because of the rarity
of the occurrence of primary malignant tumors in the
spleen. These tumors can be classified broadly as lym-
phoid and nonlymphoid. Non-Hodgkin’s lymphoma is
the most common primary lymphoid tumor, and angio-
sarcoma is the most common nonlymphoid malignant
neoplasm. The remaining nonlymphoid tumors, such as
hemangioendothelioma, malignant fibrous histiocy-
toma (MFH), fibrosarcoma, and leiomyosarcoma, are
exceedingly rare and are only anecdotally reported.
This report presents the first case of splenic malignant
fibrous histiocytoma treated by LS reported in the in-
ternational literature.
CASE REPORT
A 76-year-old man presented to the Mayo Clinic with a
4-week history of left upper quadrant abdominal and
flank pain. He had an intentional weight loss of 30 pounds
over the past 18 months. A gastrointestinal review of
systems was negative. He had no fever, sweats, or chills.
His past medical history was significant for prostate can-
cer, recurrent kidney stones secondary to cystinuria, hy-
pertension, coronary artery disease, and hyperlipidemia.
His past surgical history included multiple stone extrac-
tion procedures, including bilateral open stone extrac-
tions. He underwent radical retropubic prostatectomy and
pelvic lymphadenectomy in 1997.
On physical examination, he was well appearing, afebrile,
and normotensive. His body mass index was 25kg/m
2. His
abdomen was soft, nondistended, slightly tender to pal-
pation in the left upper quadrant; no masses or organo-
megaly were appreciated on deep palpation. Laboratory
data showed a white blood cell count of 7,300/L, hemo-
globin of 10.6g/dL, and platelets of 241,000/L. His creati-
nine was 1.4mg/dL.
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CASE REPORTAn outside CT scan of the abdomen and pelvis with oral
and intravenous contrast showed a 4.8 x 6.1 x 5-cm het-
erogenous splenic mass that was not present on a CT scan
10 months earlier (Figure 1). The mass had irregular
borders and contained enhancing nodular and cystic com-
ponents. It was reported as suspicious hemangioendothe-
lioma, angiosarcoma, hemangiopericytoma, and other
malignant processes, such as metastases or possibly infec-
tion. An incidental splenule was noted in the splenic
hilum.
An ultrasound-guided biopsy of the splenic mass re-
vealed a high-grade malignant neoplasm, unable to be
further classified on cytology. A PET scan showed a
centrally hypometabolic and peripherally hypermeta-
bolic lesion in the spleen with a small central hematoma
consistent with the biopsy done the day before. (Mul-
tiple foci of skeletal malignant type FDG uptake with
associated subtle sclerosis were seen on L1, L3, left
sacrum left iliac bone, left anterior superior iliac spine,
and subtrochanteric left femur (Figure 2). There was
circumferential uptake within a couple of loops of small
bowel in the left lower quadrant that was considered
most likely physiological. A contrast enhanced CT en-
terography confirmed noninvolvement of the bowel but
showed splenic mass enlargement to 7.1 x 5.3cm. Up-
per endoscopy and colonoscopy identified a cecal tu-
bulovillous adenoma without evidence of malignancy.
A carcinoembryonic antigen level was 0.6ng/mL (nor-
mal), and PSA was 0.10ng/mL.
Laparoscopic splenectomy, including the splenule was
performed without any intraoperative complications.
The patient had an uneventful postoperative course and
was discharged on postoperative day 2. The final pa-
thology confirmed an undifferentiated pleomorphic sar-
coma, high grade (4 of 4). Postoperatively, a CT-guided
biopsy of the left iliac bone lesion was negative for
malignancy. The patient declined any treatment that
would be based on the presumption of residual disease.
DISCUSSION
In 1881, Theodor Billroth performed the first splenectomy
for sarcoma in a 43-year-old woman with lymphosarco-
ma.2 She died 6 months later from recurrent disease. Since
that time, splenectomy has remained the preferred treat-
ment for splenic sarcomas. Malignant fibrous histiocyto-
mas are rare and have been classified into 5 subtypes:
pleomorphic, inflammatory, myxoid type, giant cell, and
angiomatoid.3 They are most commonly found in the
extremities. Intraabdominal locations account for approx-
imately 20% of MFH.4–6
We have found only 15 cases of splenic MFHs reported
in the international literature (Table 1).7–18 Thirteen of
the patients were treated with splenectomy, one patient
had the tumor found on autopsy, and one patient did
Figure 2. PET of the pelvis showing multiple foci of skeletal
malignant-type FDG uptake, including left sacrum at the level
of the S2 foramen and left iliac bone adjacent to the SI joint.
Figure 1. CT scan of the abdomen showing a 4.8-cm AP x
6.1-cm width x 5-cm length nonhomogeneous mass in the
spleen. This mass has an irregular outline and contains several
enhancing nodules and cystic spaces.
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years to 82 years, with a mean age of 53. The reported
survival ranged from 9 days to 18 months. Radiation
was given to one of these patients after splenic resec-
tion, and chemotherapy was given to one patient. One
patient was treated with combined chemotherapy and
radiation. The splenic mass ranged from 375g to 1850g
(mean, 1136). The tumor size ranged from 2.5cm to
21.5cm (mean, 12.9). To our knowledge, this is the first
reported case of a splenic pleomorphic sarcoma treated
by laparoscopic splenectomy.
Laparoscopic splenectomy has become progressively
accepted as an advantageous and safe approach for
splenectomy
. It has been shown to have reduced mor-
bidity and mortality rates compared with open splenec-
Table 1.
Cases of Splenic Malignant Fibrous Histiocytoma Reported in the International Literature
Study Case Age Gender Spleen Size Tumor Size
(cm)
Subtype Treatment Survival
Hashmi
(2009)
1 76 M 375g 7.1 x 5.3 Pleomorphic Laparoscopic
splenectomy
To date
Govoni
(1982)7
2 51 F 1400g 21 x 25 x 10 Pleomorphic Open
splenectomy
Alive at 7
months
post op
Wick (1982)8 3 48 M 1184g 8 Inflammatory Open
splenectomy
plus
radiation
Alive with
liver mets
at 18
months
4 51 F 1400g Inflammatory Open
splenectomy
Alive at 17
months
5 54 M 1235g Unknown Open
splenectomy
Alive at 3
months
Mallipudi
(1998)9
67 3 W 1 5  10  8490g 10 Pleomorphic Open
splenectomy
19 months
Colovic
(2001)10
74 5 F 1 4  12  71 1  10  7 Pleomorphic Open
splenectomy
15 months
Bonilla
(1994)11
8 42 F Unknown Splenectomy,
XRT,
chemotx
4 months
Katsuura
(2006)
3
9 82 M 13cm 2.5  3 Inflammatory Open
splenectomy
Alive at 18
months
Lieu (1993)1
2 10 71 M 1870g 9.5 Pleomorphic Open
splenectomy
9 days
Ozaras
(2003)1
3
11 51 F 12  11  10 Pleomorphic Open
splenectomy
Sieber
(1990)1
4
12 41 M 281712 1850g 21.5 Pleomorphic Open
splenectomy
6 months
Yu (1989)1
5 13 11 F 15  15  10 Inflammatory Open
splenectomy
Jinno (1987)1
6 14 53 M Pleomorphic Autopsy Autopsy
Bruneton
(1988)
17
15 54 M 20 cm Open
(partial)
splenectomy
3 months
Yuan (2006)
18 16 None
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mortality 2% vs. 18%).19 Most reports include patients
with benign diseases and small spleens. LS for malig-
nant disease can be a greater challenge, because of the
size of the spleen and the general condition of the
patient. Burch et al19 compared the outcomes of LS for
benign versus malignant neoplasms. They showed that
there was no statistically significant difference identi-
fied between those undergoing LS for benign versus
malignant disease in terms of length of stay, complica-
tion rate, or mortality. Although there were significant
differences between the 2 groups in terms of operative
time, splenic weight, and the need for an accessory
incision for spleen retrieval.
One criticism of the laparoscopic approach has been
the lack of tactile feedback and perhaps an inability to
identify accessory splenic tissue. The incidence of ac-
cessory spleen is approximately 15%.20 Failure to detect
and ablate accessory splenic tissue may lead to treat-
ment failure in case of malignancy. Studies show that
the lack of the ability to palpate does not compromise
the surgeon’s ability to find and remove accessory
splenic tissue when LS is compared to OS.21,22
Patients with splenic sarcoma may be at risk for operative
conversion to an open operation for bleeding. In fact,
hemoperitoneum due to splenic rupture is seen in up to
13% to 30% of cases and is often the first manifestation of
the disease.23
Maintaining the integrity of the capsule is advisable for
both oncological and hemostatic reasons to minimize
the chance of tumor dissemination or bleeding from the
parenchyma. It is critical to avoid iatrogenic splenic
rupture. Therefore, splenic size and surgeon experi-
ence are key determining factors when deciding on an
open, a hand-assisted, or a total laparoscopic splenec-
tomy.
CONCLUSION
Primary malignancies of the spleen are rare and are
primarily treated with splenectomy. This case report
shows that laparoscopic splenectomy is a feasible ope-
rative choice for patients with sarcomas, allowing the
advantages of laparoscopic surgery and a quicker heal-
ing process permitting earlier institution of adjuvant
treatment if necessary. The large size and increased risk
of bleeding will likely be the greatest challenges for
surgeons performing laparoscopic splenectomy for
splenic sarcomas.
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